Literature DB >> 25615797

Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview.

Anne Rouch1, Corinne Vanucci-Bacqué1, Florence Bedos-Belval2, Michel Baltas3.   

Abstract

PAI-1, a glycoprotein from the serpin family and the main inhibitor of tPA and uPA, plays an essential role in the regulation of intra and extravascular fibrinolysis by inhibiting the formation of plasmin from plasminogen. PAI-1 is also involved in pathological processes such as thromboembolic diseases, atherosclerosis, fibrosis and cancer. The inhibition of PAI-1 activity by small organic molecules has been observed in vitro and with some in vivo models. Based on these findings, PAI-1 appears as a potential therapeutic target for several pathological conditions. Over the past decades, many efforts have therefore been devoted to developing PAI-1 inhibitors. This article provides an overview of the publishing activity on small organic molecules used as PAI-1 inhibitors. The chemical synthesis of the most potent inhibitors as well as their biological and biochemical evaluations is also presented.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cardiovascular diseases; Fibrinolysis; Inhibitors; Plasminogen activator inhibitor (PAI-1); Tissue-type plasminogen activator (tPA); Urokinase plasminogen activator (uPA)

Mesh:

Substances:

Year:  2015        PMID: 25615797     DOI: 10.1016/j.ejmech.2015.01.010

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  20 in total

1.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

2.  Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment.

Authors:  Xiuqin Li; Yong Gao; Zhaoyun Meng; Cui Zhang; Qinde Qi
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

Review 3.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

4.  A compromised liver alters polychlorinated biphenyl-mediated toxicity.

Authors:  Banrida Wahlang; Jordan T Perkins; Michael C Petriello; Jessie B Hoffman; Arnold J Stromberg; Bernhard Hennig
Journal:  Toxicology       Date:  2017-02-02       Impact factor: 4.221

Review 5.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Authors:  Veronica R Placencio; Yves A DeClerck
Journal:  Cancer Res       Date:  2015-07-15       Impact factor: 12.701

6.  Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.

Authors:  Katherine B Schuetze; Matthew S Stratton; Weston W Blakeslee; Michael F Wempe; Florence F Wagner; Edward B Holson; Yin-Ming Kuo; Andrew J Andrews; Tonya M Gilbert; Jacob M Hooker; Timothy A McKinsey
Journal:  J Pharmacol Exp Ther       Date:  2017-02-07       Impact factor: 4.030

Review 7.  Physiological and pathological impact of exosomes of adipose tissue.

Authors:  Yan Zhang; Mei Yu; Weidong Tian
Journal:  Cell Prolif       Date:  2016-01-18       Impact factor: 6.831

8.  Diabetes-associated dysregulated cytokines and cancer.

Authors:  Yong Wu; Yanjun Liu; Yunzhou Dong; Jay Vadgama
Journal:  Integr Cancer Sci Ther       Date:  2016-02-15

Review 9.  Precision medicine of aneurysmal subarachnoid hemorrhage, vasospasm and delayed cerebral ischemia.

Authors:  Christian Burrell; Nicole E Avalon; Jason Siegel; Michael Pizzi; Tumpa Dutta; M Cristine Charlesworth; William D Freeman
Journal:  Expert Rev Neurother       Date:  2016-07-11       Impact factor: 4.618

Review 10.  TGF-β Physiology as a Novel Therapeutic Target Regarding Autoimmune Thyroid Diseases: Where Do We Stand and What to Expect.

Authors:  Efstratios Kardalas; Spyridoula Maraka; Maria Papagianni; George Paltoglou; Charalampos Siristatidis; George Mastorakos
Journal:  Medicina (Kaunas)       Date:  2021-06-14       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.